{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:27:35Z","timestamp":1768249655718,"version":"3.49.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sleep Medicine Reviews"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1016\/j.smrv.2004.01.004","type":"journal-article","created":{"date-parts":[[2004,6,22]],"date-time":"2004-06-22T17:29:16Z","timestamp":1087925356000},"page":"355-366","source":"Crossref","is-referenced-by-count":46,"title":["Pharmacotherapy for cataplexy"],"prefix":"10.1016","volume":"8","author":[{"given":"William C.","family":"Houghton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Scammell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Thorpy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.smrv.2004.01.004_BIB1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0361-9230(87)90019-0","article-title":"Relation of pontine choline acetyltransferase immunoreactive neurons with cells which increase discharge during REM sleep","volume":"18","author":"Shiromani","year":"1987","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.smrv.2004.01.004_BIB2","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1523\/JNEUROSCI.19-08-03057.1999","article-title":"Differential c-Fos expression in cholinergic, monoaminergic, and GABAergic cell groups of the pontomesencephalic tegmentum after paradoxical sleep deprivation and recovery","volume":"19","author":"Maloney","year":"1999","journal-title":"J Neurosci"},{"issue":"1 Pt 2","key":"10.1016\/j.smrv.2004.01.004_BIB3","first-page":"R451","article-title":"GABA release in the dorsal raphe nucleus: role in the control of REM sleep","volume":"273","author":"Nitz","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB4","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1046\/j.1460-9568.1998.00106.x","article-title":"Electrophysiological evidence that noradrenergic neurons of the rat locus coeruleus are tonically inhibited by GABA during sleep","volume":"10","author":"Gervasoni","year":"1998","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.smrv.2004.01.004_BIB5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00238666","article-title":"The hyperpolarization of spinal motoneurones by glycine and related amino acids","volume":"5","author":"Curtis","year":"1968","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.smrv.2004.01.004_BIB6","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1152\/jn.1987.57.4.1118","article-title":"Motoneuron properties during motor inhibition produced by microinjection of carbachol into the pontine reticular formation of the decerebrate cat","volume":"57","author":"Morales","year":"1987","journal-title":"J Neurophysiol"},{"issue":"Pt 3","key":"10.1016\/j.smrv.2004.01.004_BIB7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1113\/jphysiol.2002.028985","article-title":"Cessation of activity in red nucleus neurons during stimulation of the medial medulla in decerebrate rats","volume":"545","author":"Mileykovskiy","year":"2002","journal-title":"J Physiol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB8","article-title":"Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs","author":"Wu","year":"2003","journal-title":"J Physiol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/sleep\/26.3.259","article-title":"Long-lasting enhancement of rapid eye movement sleep and pontogeniculooccipital waves by vasoactive intestinal peptide microinjection into the amygdala temporal lobe","volume":"26","author":"Simon-Arceo","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0306-4522(02)00089-1","article-title":"Cataplexy-related neurons in the amygdala of the narcoleptic dog","volume":"112","author":"Gulyani","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.smrv.2004.01.004_BIB11","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(99)80023-3","article-title":"Weak with laughter","volume":"354","author":"Overeem","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.smrv.2004.01.004_BIB12","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias","volume":"59","author":"Mignot","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1096-9861(19991213)415:2<145::AID-CNE1>3.0.CO;2-2","article-title":"Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system","volume":"415","author":"Horvath","year":"1999","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB14","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.1073\/pnas.96.19.10911","article-title":"Orexin A activates locus coeruleus cell firing and increases arousal in the rat","volume":"96","author":"Hagan","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.smrv.2004.01.004_BIB15","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1152\/jn.00968.2002","article-title":"Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism","volume":"89","author":"Peever","year":"2003","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0301-0082(96)00070-6","article-title":"Pharmacological aspects of human and canine narcolepsy","volume":"52","author":"Nishino","year":"1997","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0140-6736(88)90157-2","article-title":"Prazosin contraindicated in patients with narcolepsy","volume":"2","author":"Guilleminault","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.smrv.2004.01.004_BIB18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/sleep\/12.3.254","article-title":"Exacerbation of human cataplexy by prazosin","volume":"12","author":"Aldrich","year":"1989","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB19","series-title":"The pharmacological basis of therapeutics","first-page":"447","article-title":"Drugs and the treatment of psychiatric disorders. Depression and anxiety disorders","author":"Baldessarini","year":"2001"},{"key":"10.1016\/j.smrv.2004.01.004_BIB20","first-page":"704","article-title":"Pharmacotherapy in narcolepsy","volume":"21","author":"Akimoto","year":"1960","journal-title":"Dis Nerv Syst"},{"key":"10.1016\/j.smrv.2004.01.004_BIB21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0022-510X(66)90001-3","article-title":"Treatment of narcolepsy with imipramine (Tofranil) and desmethylimipramine (Pertofran)","volume":"3","author":"Hishikawa","year":"1966","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.smrv.2004.01.004_BIB22","first-page":"418","article-title":"A note on cataplexy treated with protriptyline","volume":"30","author":"Gross","year":"1969","journal-title":"Dis Nerv Syst"},{"key":"10.1016\/j.smrv.2004.01.004_BIB23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1176\/ajp.134.2.183","article-title":"Protriptyline: an effective agent in the treatment of the narcolepsy\u2013cataplexy syndrome and hypersomnia","volume":"134","author":"Schmidt","year":"1977","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.smrv.2004.01.004_BIB24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.1.5750.670-c","article-title":"Treatment of narcolepsy","volume":"1","author":"Bourdillon","year":"1971","journal-title":"Br Med J"},{"key":"10.1016\/j.smrv.2004.01.004_BIB25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archneur.1974.00490310092014","article-title":"On the treatment of rapid eye movement narcolepsy","volume":"30","author":"Guilleminault","year":"1974","journal-title":"Arch Neurol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1176\/ajp.137.2.237","article-title":"Characteristics of therapeutic response to imipramine in cataplectic men","volume":"137","author":"Linnoila","year":"1980","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.smrv.2004.01.004_BIB27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archneur.1974.00490400069008","article-title":"A study on cataplexy","volume":"31","author":"Guilleminault","year":"1974","journal-title":"Arch Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.smrv.2004.01.004_BIB28","first-page":"86","article-title":"The use of clomipramine as an REM sleep suppressant in narcolepsy","volume":"56","author":"Chen","year":"1980","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.smrv.2004.01.004_BIB29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/archneur.1975.00490520023002","article-title":"Treatment of cataplexy with clomipramine","volume":"32","author":"Shapiro","year":"1975","journal-title":"Arch Neurol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1600-0404.1976.tb07621.x","article-title":"Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride","volume":"54","author":"Guilleminault","year":"1976","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.smrv.2004.01.004_BIB31","first-page":"607","article-title":"Severe hypermotility during sleep in treatment of cataplexy with clomipramine","volume":"15","author":"Bental","year":"1979","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.smrv.2004.01.004_BIB32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(79)92495-4","article-title":"Clomipramine and clonazepam in cataplexy","volume":"2","author":"Parkes","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.smrv.2004.01.004_BIB33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2869.1995.tb00159.x","article-title":"Treatment in the narcoleptic syndrome: self assessment of the action of dexamphetamine and clomipramine","volume":"4","author":"Chen","year":"1995","journal-title":"J Sleep Res"},{"key":"10.1016\/j.smrv.2004.01.004_BIB34","unstructured":"USP Dispensing Information, Greenwood Village, CO:MICROMEDEX; 2002."},{"key":"10.1016\/j.smrv.2004.01.004_BIB35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.135.5.385","article-title":"Sleep, depression and antidepressants","volume":"135","author":"Chen","year":"1979","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.smrv.2004.01.004_BIB36","first-page":"113","article-title":"Status cataplecticus induced by abrupt withdrawal of clomipramine","volume":"17","author":"Martinez-Rodriguez","year":"2002","journal-title":"Neurologia"},{"key":"10.1016\/j.smrv.2004.01.004_BIB37","first-page":"127","article-title":"Interaction of modafinil and clomipramine as comedication in a narcolepstic patient","volume":"21","author":"Gr\u00f6zinger","year":"1998","journal-title":"Clin Neuropharmcol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00002826-198606000-00001","article-title":"Clinical pharmacology of monoamine oxidase inhibitors","volume":"9","author":"McDaniel","year":"1986","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM197110282851802","article-title":"Treatment of intractable narcolepsy with a monoamine oxidase inhibitor","volume":"285","author":"Wyatt","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smrv.2004.01.004_BIB40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/sleep\/10.5.491","article-title":"Selegiline in narcolepsy","volume":"10","author":"Roselaar","year":"1987","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB41","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1212\/WNL.44.11.2095","article-title":"Selegiline in the treatment of narcolepsy","volume":"44","author":"Hublin","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.smrv.2004.01.004_BIB42","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00002826-199508000-00002","article-title":"Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study","volume":"18","author":"Mayer","year":"1995","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1055\/s-2007-979599","article-title":"Tranylcypromine in narcolepsy","volume":"28","author":"Gernaat","year":"1995","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.smrv.2004.01.004_BIB44","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2869.1993.tb00096.x","article-title":"Treatment of narcolepsy\u2013cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine\u2014a pilot study","volume":"2","author":"Hohagen","year":"1993","journal-title":"J Sleep Res"},{"key":"10.1016\/j.smrv.2004.01.004_BIB45","series-title":"American Hospital Formulary Service Drug Information 2003","year":"2003"},{"key":"10.1016\/j.smrv.2004.01.004_BIB46","series-title":"Clinical toxicology","first-page":"546","article-title":"Monoamine oxidase inhibitors","author":"Mendelsohn","year":"2001"},{"key":"10.1016\/j.smrv.2004.01.004_BIB47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/pgmj.70.819.34","article-title":"A patient with coexisting narcolepsy and morbid jealousy showing favourable response to fluoxetine","volume":"70","author":"Wing","year":"1994","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.smrv.2004.01.004_BIB48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp.43.2.171","article-title":"Fluvoxamine and clomipramine in the treatment of cataplexy","volume":"43","author":"Schachter","year":"1980","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.smrv.2004.01.004_BIB49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00002826-198602000-00004","article-title":"The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients","volume":"9","author":"Godbout","year":"1986","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1600-0404.1986.tb03518.x","article-title":"The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo","volume":"74","author":"Schrader","year":"1986","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.smrv.2004.01.004_BIB51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000115821","article-title":"Efficacy of trazodone in narcolepsy","volume":"24","author":"Sandyk","year":"1985","journal-title":"Eur Neurol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB52","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1212\/WNL.44.4.707","article-title":"Fluoxetine suppresses human cataplexy: a pilot study","volume":"44","author":"Frey","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.smrv.2004.01.004_BIB53","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/sleep\/9.2.371","article-title":"Fluoxetine in the treatment of cataplexy","volume":"9","author":"Langdon","year":"1986","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB54","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1389-9457(00)00026-5","article-title":"The use of citalopram in resistant cataplexy","volume":"1","author":"Thirumalai","year":"2000","journal-title":"Sleep Med"},{"issue":"Suppl 1","key":"10.1016\/j.smrv.2004.01.004_BIB55","first-page":"217","article-title":"Venlafaxine in the treatment of the narcoleptic syndrome","volume":"5","author":"Smith","year":"1996","journal-title":"J Sleep Res"},{"issue":"1 Pt 2","key":"10.1016\/j.smrv.2004.01.004_BIB56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/sleep\/9.1.275","article-title":"Viloxazine hydrochloride in narcolepsy: a preliminary report","volume":"9","author":"Guilleminault","year":"1986","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB57","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/sleep\/24.3.282","article-title":"Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study","volume":"24","author":"Larrosa","year":"2001","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB58","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/14656566.4.7.1165","article-title":"Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit\/hyperactivity disorder","volume":"4","author":"Kratochvil","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.smrv.2004.01.004_BIB59","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1389-9457(00)00056-3","article-title":"Narcolepsy and obesity: remission of severe cataplexy with sibutramine","volume":"2","author":"Krahn","year":"2001","journal-title":"Sleep Med"},{"key":"10.1016\/j.smrv.2004.01.004_BIB60","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0306-3623(92)90282-O","article-title":"Significance of \u03b3-hydroxybutyric acid in the brain","volume":"23","author":"Tunnicliff","year":"1992","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB61","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0301-0082(96)00064-0","article-title":"The \u03b3-hydroxybutyrate signaling system in brain: organization and functional implications","volume":"51","author":"Maitre","year":"1997","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB63","first-page":"273","article-title":"The effects of gamma-hydroxybutyrate on sleep","volume":"12","author":"Mamelak","year":"1977","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.smrv.2004.01.004_BIB64","first-page":"23","article-title":"Effects of nocturnal gamma-hydroxybutyrate on sleep\/wake patterns in narcolepsy\u2013cataplexy","volume":"7","author":"Broughton","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.smrv.2004.01.004_BIB65","first-page":"222","article-title":"The effects and effectiveness of \u03b3-hydroxybutyrate in patients with narcolepsy","volume":"46","author":"Scharf","year":"1985","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.smrv.2004.01.004_BIB66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0006-3223(89)90048-6","article-title":"Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy\u2013cataplexy: double blind subjective measures","volume":"26","author":"Scrima","year":"1989","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.smrv.2004.01.004_BIB67","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/sleep\/16.3.216","article-title":"Gamma-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study","volume":"6","author":"Lammers","year":"1993","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB68","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/sleep\/13.6.479","article-title":"The effects of \u03b3-hydroxybutyrate on the sleep of narcolepsy patients: a double blind study","volume":"13","author":"Scrima","year":"1990","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB69","first-page":"42","article-title":"A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy","volume":"25","year":"2002","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB70","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1081\/CLT-120019128","article-title":"The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms","volume":"41","year":"2003","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB71","first-page":"31","article-title":"A 12-month, open-label, multi-center extension trial of orally administered sodium oxybate for the treatment of narcolepsy","volume":"26","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB72","unstructured":"Product labeling. Xyrem\u00ae (sodium oxybate) oral solution. Orphan Medical, Inc."},{"issue":"Suppl","key":"10.1016\/j.smrv.2004.01.004_BIB73","first-page":"A474","article-title":"Effect of increasing doses of sodium oxybate on nocturnal oxygen saturation: preliminary findings","volume":"25","author":"Black","year":"2002","journal-title":"Sleep"},{"issue":"Suppl","key":"10.1016\/j.smrv.2004.01.004_BIB74","first-page":"A473","article-title":"Analysis of dose effects of sodium oxybate on noctural respiratory disturbances","volume":"25","author":"Ristanovic","year":"2002","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB75","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-2007-973527","article-title":"4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn of GABA metabolism","volume":"29","author":"Gibson","year":"1998","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.smrv.2004.01.004_BIB76","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1172\/JCI119587","article-title":"Simultaneous stimulation of slow-wave sleep and growth hormone secretion by \u03b3-hydroxybutyrate in normal young men","volume":"100","author":"Van Cauter","year":"1997","journal-title":"J Clin Invest"},{"issue":"Suppl","key":"10.1016\/j.smrv.2004.01.004_BIB77","first-page":"A87","article-title":"decreased body-mass index (BMI) in narcolepstic patients treated with sodium oxybate","volume":"26","author":"Ristanovic","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB78","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/archneur.1979.00500460084015","article-title":"Successful treatment of narcolepsy with propranolol: a case report","volume":"36","author":"Kales","year":"1979","journal-title":"Arch Neurol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB79","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/0003-4819-91-5-741","article-title":"Propranolol in the treatment of narcolepsy","volume":"91","author":"Kales","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.smrv.2004.01.004_BIB80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/sleep\/8.2.95","article-title":"Propranolol: long-term treatment in narcolepsy\u2013cataplexy","volume":"8","author":"Meier-Ewert","year":"1985","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB81","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/archneur.1983.04050120078016","article-title":"Cataplexy relieved by tiapride","volume":"40","author":"Paulus","year":"1983","journal-title":"Arch Neurol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB82","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/j.1875-9114.1996.tb02979.x","article-title":"Effective treatment of narcolepsy with codeine in a patient receiving hemodialysis","volume":"16","author":"Benbadis","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.smrv.2004.01.004_BIB83","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/sleep\/19.2.101","article-title":"Carbamazepine as a treatment for cataplexy","volume":"19","author":"Vaughn","year":"1996","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB84","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1468-1331.2000.00087.x","article-title":"Problems associated with switch to modafinil\u2014a novel alerting agent in narcolepsy","volume":"7","author":"Guilleminault","year":"2000","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.smrv.2004.01.004_BIB85","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0404.1979.tb02976.x","article-title":"Mazindol in the treatment of narcolepsy","volume":"60","author":"Parkes","year":"1979","journal-title":"Acta Neurol Scand"},{"issue":"1 Pt 2","key":"10.1016\/j.smrv.2004.01.004_BIB86","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/sleep\/9.1.265","article-title":"Therapeutic effects of mazindol on narcolepsy","volume":"9","author":"Iijima","year":"1986","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB87","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0278-5846(88)90014-0","article-title":"Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil","volume":"12","author":"Bastuji","year":"1988","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.smrv.2004.01.004_BIB88","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2869.2001.00234.x","article-title":"Health-related quality of life in narcolepsy","volume":"10","author":"Daniels","year":"2001","journal-title":"J Sleep Res"},{"key":"10.1016\/j.smrv.2004.01.004_BIB89","first-page":"451","article-title":"Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: an update for 2000","volume":"24","author":"Littner","year":"2001","journal-title":"Sleep"},{"key":"10.1016\/j.smrv.2004.01.004_BIB90","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1389-9457(00)00081-2","article-title":"Current concepts in the etiology, diagnosis and treatment of narcolepsy","volume":"2","author":"Thorpy","year":"2001","journal-title":"Sleep Med"},{"key":"10.1016\/j.smrv.2004.01.004_BIB91","doi-asserted-by":"crossref","DOI":"10.2165\/00002018-200427050-00002","article-title":"The Xyrem\u00ae Risk Management Program","author":"Fuller","year":"2004","journal-title":"Drug Safety"}],"container-title":["Sleep Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087079204000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087079204000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T17:17:56Z","timestamp":1734455876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1087079204000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S1087079204000061"],"URL":"https:\/\/doi.org\/10.1016\/j.smrv.2004.01.004","relation":{},"ISSN":["1087-0792"],"issn-type":[{"value":"1087-0792","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}